Диагностическое и прогностическое значение антимитохондриальных антител и цитокинов при первичном билиарном циррозе
Диссертация
Изучение холестатических заболеваний печени является актуальной проблемой современной гепатологии. Первичный билиарный цирроз (ПБЦ) -хроническое прогрессирующее заболевание невыясненной этиологии с деструктивным поражением внутрипеченочных желчных протоков, развитием хронического холестаза, портального и перипортального воспаления, формированием цирроза печени. В связи с совершенствованием… Читать ещё >
Список литературы
- Агафонова Р.А., Яковенко Э. П., Григорьев П. Я. и соавт. Урсодезоксихолевая кислота в терапии ПБЦ. // Фальк симпозиум № 92. Новые направления в гепатологии: Тезисы стендовых докладов. 1996. — С. 15.
- Аруин Л.И. Апоптоз и патология печени. // Российский журнал гастроэнтерол., гепатол., колопроктол. 1998. — № 2. — С. 6 — 11.
- Аруин Л.И. Апоптоз при патологических процессах в органах пищеварения. // Клиническая медицина. 2000. — № 1.- С. 5 — 10.
- Буеверов А.О. Патогенез аутоиммунных заболеваний печени. // Российский журнал гастроэнтерол., гепатол., колопроктол. 2001. — № 4. — С. 59 — 61.
- Бюрроуз Э. Первичный билиарный цирроз. // Российский журнал гастроэнтерол., гепатол., колопроктол. 2001. — № 4. — С. 61 — 62.
- Высоцкая Р.А., Логинов А. С. Роль простагландинов в патогенезе ПБЦ. // Фальк симпозиум № 92. Новые направления в гепатологии: Тезисы стендовых докладов. 1996. — С. 73.
- Григорьев П.Я., Яковенко Э. П., Саяпина Е. С. и соавт. Концентрация первичных желчных кислот в сыворотке крови больных ПБЦ. // Фальк -симпозиум № 92. Новые направления в гепатологии: Тезисы стендовых докладов. 1996.-С. 95.
- Гусева О.А., Цодиков Г. В., Сучков С. В. и соавт. Особенности иммунного статуса у больных ПБЦ. // Фальк симпозиум № 92. Новые направления в гепатологии: Тезисы стендовых докладов. 1996. — С. 107.
- Ивашкин В.Т., Буеверов А. О. Аутоиммунные заболевания печени в практике клинициста. М.: М-Вести. 2001.- 102 с.
- Кашкин К.П. Цитокины иммунной системы: основные свойства и иммунобиологическая активность // Клин, лабор. диагностика. 1998. — № 11. — С 21−32.• 142
- Клиническая иммунология. Руководство для врачей. / Под ред. Е. И. Соколова. М.: Медицина.- 1998. — 272 с.
- Лейшнер У. Практическое руководство по заболеваниям желчных путей: Пер. с нем.- М.: Гэотар-Мед.- 2001.- 256 с.
- Логинов А.С., Аруин Л. И. Клиническая морфология печени. М.: Медицина. 1985.- 181 с.
- Логинов А.С., Царегородцева Т. М., Зотина М. М. Иммунная система и болезни органов пищеварения.- М.: Медицина. 1986. — 256 с. 15.' Майер К. П. Гепатит и последствия гепатита: Пер. с нем.- М.: Гэотар Мед.-1999.- 427 с.
- Маммаев С.Н., Буеверов А. О. Апоптоз лимфоцитов крови у больных хроническим гепатитом С. // Российский журнал гастроэнтерол., гепатол., колопроктол.: Матер, седьмой росс, гастроэнтерол. недели. 2001. — № 5. -С. 83.
- Москалева Е.Ю. Молекулярно-биохимические механизмы развития вторичных иммунодефицитных состояний при действии различных экологических факторов: Дисс.. д-ра биол. наук. М. — 1998. — 346 с.
- Новик А.А., Ионова Т. И. Руководство по исследованию качества жизни в медицине. Спб.: Нева, М.: Олма-Пресс. — 2002. — 320 с.
- Патрушев Л.И. Экспрессия генов. М.: Наука.- 2000. — 527 с.
- Подымова С.Д. Современные представления о патогенезе и терапии внутрипеченочного холестаза // Русский медицинский журнал. 2001. -Том 3, № 2.- С. 66−69.
- Прока Н.В. Первичный билиарный цирроз печени (клиника, диагностика, лечение): Дисс.. канд. мед. наук. -М.- 1984. 128 с.
- Решетняк В.И. Механизм развития внутрипеченочного холестаза и лечение больных первичным билиарным циррозом печени: Дисс. .д-ра мед. наук. -М.- 1996.-280 с.
- Фрадкин Г. Е., Рабинкова Е. В., Торосян М. В. и др. Роль взаимодействия in vitro белков ssb с ДНК-полимеразой // Мол. Биол. 1998.- № 22. — С 111 — 116.
- Шерлок Ш., Дули Дж. Заболевания печени и желчных путей: Пер. с англ.
- М.: Гэотар Медицина.- 1999. 859 с. Ч
- Яковенко Э.П., Григорьев П. Я., Агафонова Н. А., Яковенко А. В. Внутрипеченочный холестаз от патогенеза к лечению. // Практикующий врач.- 1998.-№ 13.-С. 20−23.
- Abastado J. Apoptosis: function and regulation of cell death // Res. Immunol. -1996.-Vol. 47.-P. 443−456.
- Afford S.C., Ahmed-Choudhury J., Randhawa S. et al. CD40 activation-induced, Fas-dependent apoptosis and NF-kappaB/AP-1 signaling in human intrahepatic biliary epithelial cells.//Faseb J. 2001. — Vol. 15, N 13.-P. 2345 -2354.
- Akbar S.M., Yamamoto K., Miyakawa H. et al. Peripheral blood T-cell responses to pyruvate dehydrogenase complex in primary biliary cirrhosis: role of antigen-presenting dendritic cells. // Eur. J. Clin. Onvest. 2001. — Vol. 31, N 7.-P. 639−646.
- Angulo P., Jorgensen R.A., Keach J.C. et al. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. // Hepatol. 2000. — Vol. 31, N 2. — P. 318 — 323.
- Angulo P., Jorgensen R.A., Lindor K.D. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile? // Am. J. Gastroenterol. 2001. — Vol. 96, N 11. — P. 3152 — 3157.
- Bateson M.C., Gedling P. Ursodeoxycholic acid therapy for primary biliary cirrhosis. A 10-year British single-center population-based audit of efficacy and survival. // Postgraduate Med. J. 1998. — Vol. 874, N 74. — P. 482 — 485.
- Battista S., Fabrizio В., Mengozzi G. et al. Evidence of an increased nitric oxyde production in primary biliary cirrhosis. // Amer. J. of Gastroenterol. 2001. -Vol. 96, N3.- P. 869−875.
- Bergasa N.V., Schmitt J.M., Talbot T.L. et al. Open-label trial of oral nalmefene therapy for pruritus of cholestasis. // Hepatol. 1998. — Vol. 27, N 3. — P. 679 -684.
- Birnboim H.C., Jevcak J.J. Fluorimetric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation // Cancer Res. 1981. — Vol. 41. — P. 1889 — 1892.
- Brawn K., Fridovich I. DNA strand scission by enzymically generated radicals // Arch. Biochem. And Biophys. 1981. — Vol. 206. — P. 414 — 419.
- Caballeria L., Pares A., Castells A. et al. Hepatocellular carcinoma in primary biliary cirrhosis: Similar incidence to that in hepatitis С virus-related cirrhosis. // Am. J. Gastroenterol. 2001. — N 96. — P. 1160 — 1163.
- Cauch-Dudek K., Abbey S., Stewart D.E. et al. Fatigue in primary biliary cirrhosis.//Gut. 1998.-Vol. 43, N5.-P. 705−710.
- Chazouilleres O., Wendum D., Serfaty L. et al. Primary biliary cirrhosis autoimmune hepatitis overlap syndrome: clinical features and response totherapy. // Hepatol. 1998. — Vol. 28, N 2. — P. 296 — 301.
- Christensen E. Primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC): with treatment are of value? // J. of Hepatol. 2002. — Vol. 36, Issue 1. -P. 151 — 160.
- Comay D., Cauch-Dudek K., Hemphill D. et al. Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis? // Dig. Dis. Sci. 2000. — Vol. 45, N 10. — P. 2018 — 2021.
- Copaci I., Micu L., Cojocaru L. Ursodeoxycholic acid and methotrexate for primary biliary cirrhosis. // J. of Hepatol., Abstr. of the 36th Annual Meeting of• the Eur. Ass. for the Study of the Liver. 2001. — P/C02/24.
- Corpechot C., Barbu V., Chazouilleres O. et al. Fetal microchimerism in primary biliary cirrhosis. // J. of Hepatol. 2000. -Vol. 33, Issue 5. — P. 696 — 700.
- Corpechot C., Benlian P. Barbu V. et al. Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis. // J. Hepatol. 2001. -Vol. 35, N3.-P. 412−415.
- Corpechot C., Carrat F., Poupon R. et al. Primary biliary cirrhosis: incidence and predictine factors of cirrhosis development in ursodiol-trated patients. // Gastroenterol. 2002. — Vol. 122, N 3. — P. 652 — 658.
- Csepregi A., Kayser A., Kneip S. et al. Two B-cell autoepitopes are recognized on the human BCKADC-E2 by PBC sera. // J. of Hepatol., Abstr. of the 36lh Annual Meeting of the Eur. Ass. for the Study of the Liver. 2001. — P/C09/04.
- Deguchi A., Arima K., Masaki T. et al. Enhanced expression of Bcl-2 in • lymphocytes infiltrating into the liver of patients with primary biliary cirrhosis. //1.t. J. Mol. Med. 2002. — Vol. 9, N 6. — P. 571 — 577.
- Dienes H.P., Erberich H., Dries V. et al. Autoimmune hepatitis and overlap syndromes. // Clin. Liver Dis. 2002. — Vol. 6, N 2. — P. 349 — 362.
- Dienes H.P., Lohse A.W., Gerken G. et al. Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. // Virchows Archiv. 1997. — Vol. 431, N 2. — P. 119 — 124.
- Dohmen K., Shigematsu H., Miyamoto Y. et al. Atrophic corpus gastritis and Helicobacter pylori infection in primary biliary cirrhosis. // Digestive diseasesand sciences. 2002. — Vol. N 47, N 1. — P. 162 — 169.
- Donaldson P., Agarwal K., Craggs A. et al. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. // Gut. 2001. — Vol. 48, N 3. — P. 397 — 402.
- Fanning P.A., Jonsson J.R., Clouston A.D. et al. Detection of male DNA in the liver of female patients with primary biliary cirrhosis. // J. of Hepatol. 2000. -Vol. 33, Issue 5.-P. 690−695.
- Faust T.W. Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. // Liver Transpl. 2001. -Nil, — Suppl 1.-P. 99−108.
- Feudjo M., Vlachogiannakos J., Carpenter J. et al. Bilirubin and albumin relationships in primary biliary cirrhosis: effect of UDSA. // J. of Hepatol., Abstr. of the 36th Annual Meeting of the Eur. Ass. for the Study of the Liver. 2001. -P/C09/12.
- Flisiak R., Wiercinska-Drapalo A., Prokopowicz D. Antibodies against M2-antigen in differential diagnosis of primary biliary cirrhosis. // Pol. Merkuriuz. Lek. 2000. — Vol. 8, N 48. — P. 373 — 375.
- Floreani A., Baragiotta A., Pizzuti D. et al. Defect of mucosal IgA in primary biliary cirrhosis (PBC). // J. of Hepatol. Abstr. of the 36th Annual Meeting of the Eur. Ass. for the Study of the Liver. 2001. — P/C09/13.
- Floreani A., Patrnoster D., Mega A. et al. Sex hormone profile and endometrial- ' cancer risk in primary biliary cirrhosis: a case-control study. // Eur. J. Obstet.
- Gynecol. Reprod. Biol. 2002. — Vol. 103, N 2. — P. 154 — 157.
- Floreani A., Tizian L., Luisetto G. et al. Effect of alendronate sodium on severe osteodystrophy in postmenopausal patients with primary biliary cirrhosis: A pilot study. // Curr. Ther. Res. 1998. — Vol. 59, N 8. — P. 589 — 593.
- Floreani A., Venturi C., Fabris P. et al. Circularting tumor necrosis factor (TNF) in primary biliary cirrhosis (PBC) and HCV related chronic active hepatitis (САН). // Hepatol. Rap. Lit. Rev. — 1992. — Vol. N 22, N 9. — P. — 278.
- Floreani A., Zappala F., Marchiori M. et al. Different response to ursodeoxycholic acid (UDSA) in primary biliary cirrhosis (PBC). // Hepatol. Rap. Lit. Rev. 1992. — Vol. N 22, N 9. — P. — 288.
- Fox C.K., Furtwaengler A., Nepomuceno R.R. et al. Apoptosis pathways in primary biliary cirrhosis and autoimmune hepatitis. // Liver. 2001. — Vol. 21, N 4.-P. 272−279.
- Fujioka S., Yamamoto K., Okamoto R. et al. Laparoscopic features of primary biliary cirrhosis in AMA-positive and AMA-negative patients. // Endoscopy. -2002. Vol. 34, N 4. — P. 318 — 321.
- Fukuchima N., Ikematsu H., Nakamura M. et al. Nucleotide variations amongst V (H) Genes of AMA-producing В cell clones in primary biliary cirrhosis. // J. Autoimmun. 2000. — Vol.14, N 3. — P. 247 — 257.
- Gershwin M.E., Ansari A.A., Mackay I.R. et al. Primary biliary cirrhosis: orchestrated immune response against epithelial cells. // Immunol. Rev. 2000. -N 174.-P. 210−225.
- Gershwin M.E., Leung P. S., Li H. et al. Primary biliary cirrhosis and autoimmunity: evaluating the genetic risk. // Isr. Med. Assoc. 2000. — Dec. -Suppl. 2.-P. 7- 10.
- Gindro Т., Arrigoni A., Martinasso F. et al. Monoethyl glycine xylidide (MEGX) test evalution in primary biliary cirrhosis: comparison with Mayo score. // Eur. J. of Gastroenterol, and Hepatol. 1997. — Vol. 9, N 12. — P. 1155 — 1159.
- Gluud C., Christensen E. In: The Cochrane Library, Issue 2. Oxford: Update Software, 2002.
- Gluud C., Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. // Cochrane Database Syst. Rev. 2002. — N 1. — CD000551.
- Goldblatt J., Taylor P.J., Lipman T. et al. The true impact of fatigue in primary biliary cirrhosis: a population study. // Gastroenterol. 2002. — Vol. 122, N 5. -P. 1235- 1241.
- Goldstein N.S., Soman A., Gordon S.C. Portal tract eosinophis and hepatocyte cytokeratin 7 immunoreactivity helps distinguish early-stage, mildly active primary biliary cirrhosis and autoimmune hepatitis. // Am. J. Clin. Pathol. -2001.-N 6.-P. 846−853.
- Graham A.M., Dollinger M.M., Howie S.E.M. et al. Bile duct cells in primary biliary cirrhosis are 'primed' for apoptosis. // Eur. J. of Gastroenterol, and Hepatol. 1998. — Vol. 10, N 7. — P. 553 — 557.
- Gregorio G.V., Portmann В., Mowat A.P. et al. A 12-year-old girl with antimitochondrial antibody-positive autoimmune hepatitis. // J. of Gastroenterol. 1997. — Vol. 27, N 4. — P. 751 — 754.
- Harada K., Furubo S., Ozaki S. et al. Increased expression of WAF1 in intrahepatic bile ducts in primary biliary cirrhosis relates to apoptosis. // J. Hepatol. 2001. — Vol. 34, N 4. — P. 500 — 506.
- Harada K., Ozaki S., Gershwin M.E. et al. Enhanced apoptosis relates to bile duct in primary biliary cirrhosis. // Hepatol. 1997. — Vol. 26, N 6. — P. 1399 — 1405.
- Harada K., Tsuneyama K., Hiramatsu K. et al. Significance of CD30-positive lymphocytes in livers in primary biliary cirrhosis. // J. Gastroenterol. 1999. -Vol. 14, N 12.-P. 1197- 1202.
- Harada K., Tsuneyama K., Yasoshima M. et al. Type 1 and type 2 memory T cells imbalance shown by expression of intrahepatic chemokine receptors relates to pathogenesis of primary biliary cirrhosis. // Hepatol. Res. 2002. — Vol. 24, N 3.-P. 290.
- Hazama H., Omagari K., Masuda J. et al. Serial changes in enzyme inhibitory antibody to pyruvate dehydrogenase complex during the course of primary biliary cirrhosis. // J. Clin. Lab. Anal. 2000. — Vol. 14, N 5. — P. 208 — 213.
- Herold C., Ganslmayer M., Deynet C. et al. Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis. // Liver. 2002. — Vol. 22, N 2. — P. 159 — 165.
- Hiasa Y., Akbar S.M., Abe M. et al. Dendritic cell subtypes in autoimmune liver diseases- decreased expression of HLA DR and CD123 on type 2 dendritic cells. // Hepatol. 2002. — Vol. 22, N 4. — P. 241 — 249.
- Hokari A., Zeniya M., Esumi H. et al. Detection of serum nitrite and nitrate in primary biliary cirrhosis: possible role of nitric oxide in bile duct injury. // J. Gastroenterol, and Hepatol. 2002. — Vol. 17, N 3. — P. 308 — 315.
- Holtmeier J., Leuschner U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. // Digestion. 2001. — Vol. 64, N 3. — P. 137 -150.
- Hoogstraten H.J.F., Smet M.B.M., Renooij W. et al. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. // Aliment. Pharmacol. And Therapeut. 1998. — Vol. 12, N10.-P. 965−971.
- Howel D., Metcalf J.V., Gray J. et al. Cancer risk in primary biliary cirrhosis: a study in northern England. // Gut. 1999. — Vol. 45, N 5. — P. 756 — 760.
- Huet P.M., Deslauriers J., Tran A. et al. Impact of fatigue on the quality of patients with primary biliary cirrhosis. // Am. J. Gastroenterol. 2000. — Vol. 95, N3.-P. 760−767.
- Ide Т., Sata M., Nakano H. et al. Increased serum IgM class anti-lipid A antibody and therapeutic effect of ursodeoxycholic acid in primary biliary cirrhosis. // Hepato-Gastroenterol. 1997. — Vol. 44, N 18. — P. 1569 — 1573.
- Ikuno N., Mackay I.R., Jois J. et al. Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis. // J. Gastroenterol, and Hepatol.-2001.-Vol. 16, N 12.-P. 1390- 1394.
- Ikuno N., Scealy M., Davies J.M. et al. A comparative study of antibody expressions in primary biliary cirrhosis and autoimmune cholangitis using phage display. // Hepatol. 2001. — Vol. 34, N 3. — P. 478 — 486.
- Inada H., Yosshizawa К., Ota M. et al. T cell receptore in the liver of patients with primary biliary cirrhosis. // Hum. Immunol. 2000. — Vol. 61, N 7. — P. 675 -683.
- Innarella R., Leto M., Farina M. et al. Antiphospholipid antibodies in patients with primary biliary cirrhosis (PBC): marker of advanced liver disease or predictive of progressive liver diseases? // J. of Hepatol. 2001. — Vol. 34, Suppl. l.-P. 188.
- Internizzi P., De Andres C., Sirchia S.M. et al. Blood fetal microchimerism in primary biliary cirrhosis. // Clin. Exp. Immunol. 2000. — Vol. 122, N 3. — P. 418−422.
- Invernizzi P., Podda M., Battezzati P.M. et al. Autoantibodies against nuclear pore complexes are associated more active and severe liver disease in primary biliary cirrhosis. // J. Hepatol. 2001. -N 34. — P. 366 — 372.
- Iwata M., Harada K., Hiramatsu K. et al. Fas ligand expressing mononuclear cells around intrahepatic bile ducts co-express CD68 in primary biliary cirrhosis.//Liver. 2000. — Vol. 20, N 2. — P. 129- 135.
- Jones D.E. Autoantigens in primary biliary cirrhosis. // J. Clin. Pathol. 2000. -. Vol.53, N11.-P. 813−821.
- Jones D.E. Fetal microchimerism: an aetiological factor in primary biliary cirrhosis. // J. of Hepatol. 2000. -Vol. 33, Issue 5. — P. 834 — 837.
- Jones D.E., Metcalf J.V., Collier J.D. et al. Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes. // Hepatol. 1997. — Vol. 26, N 5. -P. 1138−1142.
- Jones D.E., Palmer J.M., Burt A.D. et al. Bacterial motif DNA as an adjuvant for the breakdown of immune self-tolerance to pyruvate dehydrogenase complex. // Hepatol. 2002. — Vol. 36, N 3. — P. 679 — 686.
- Jones D.E., Palmer J.M., Leon M.P. et al. T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function. // Gut. 1997. — Vol. 40, N 2. — P. 2777 — 283.
- Jones E.A., Kate F.J., Borg F. et al. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. // Eur. Gastroenterol, and Hepatol. 1999. — Vol. 11, N 10. — P. 1165 — 1169.
- Jong-Hon K., Yajima R., Karino Y. et al. Development of a new enzyme-linked immunosorbent assay for the detection of anti-M2 in primary biliary cirrhosis. // Hepatol. Res. 2001. — Vol. 21, N 1. — P. 1 — 7.
- Joplin R.E., Wallace L.L., Lindsay J.G. et al. The human biliary epithelial cell plasma membrane antigen in primary biliary cirrhosis: Pyruvate dehydrogenase X?//Gastroenterol. 1997.-Vol. 11, N 5. — P. 1727 — 1733.
- Joschi S., Cauch-Dudek K., Wanless I.R. et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. // Hepatol. 2002. — Vol. 35, N 2. — P. 409 — 413.
- Joshi S., Cauch-Dudek K., Heathcote E.J. et al. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? // Am. J. Gastroenterol. 2002. — Vol. 97, N 4. — P. 999 — 1002.
- Kang J.H., Yajima R., Yoshiyasu K. et al. Development of a ELISA for the detection of anti-M2 in primary biliary cirrhosis. // J. of Hepatol., Abstr. of the 36th Annual Meeting of the Eur. Ass. for the Study of the Liver. 2001. -P/C09/23.
- Kanzler S., Bozkurt S., Herkel J. et al. Presense of SLA/LP autoantibodies in patients with primary biliary cirrhosis as a marker for secondary autoimmunehepatitis (overlap syndrome). 11 Dtsch. Med. Wochenschr. 2001. — Vol. 126, N 16.-P. 450−456.
- Kikuchi K. Immunoreactivity of recombinant human oxo-glutarate dexydrogenase complex (OGDC)-E2 protein in primary biliary cirrhosis. // Hepatol. Res. 2000. — Vol. 16, N 3. — P. 211 — 223.
- Kim W.R., Lindor K.D., Locke G.R. et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. // Gastroenterol. 2000. — Vol. 119, N 6. — P. 1631 — 1636.
- Kisand K.E., Metskula K., Kisand K.V. et al. The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples. // J. Gastroenter. 2001. — N 36. — P. 248 -254.
- Kita H., Mackay I.R., Water V.D. et al. The lymphoid liver: consideration on pathways to autoimmune injury. // Gastroenterol. 200. — Vol. 120, N 6. — P. 1485−1501.
- Kita H., Matsumura S., He X.S. et al. Analysis of TCR antagonism and molecular mimicry of an HLA-A0201-restricted CTL epitope in primary biliary cirrhosis. // Hepatol. 2002. — Vol. 36, N 4, Pt 1. — P. 918 — 926.
- Kita H., Matsumura S., He X.S. et al. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis. // J. Clin. Invest. 2002. — Vol. 109, N 9. — P. 1231 — 1240.
- Kita H., Naidenko O.V., Kronenberg M. et al. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human
- CDldtetramer.// Gastroenterol. -2002. -Vol. 123, N4.-P. 1031 1043.
- Komatsu Т., Morizane Т. Hepatocellular carcinoma and survival in patients with primary biliary cirrhosis. // Hepatol. 2002. — Vol. 35, N 5. — P. 1172• 1178.
- Kouraklis G., Glinavou A., Karatzas G. Primary biliary cirrhosis accompanied by CREST syndrome. // South. Med. 2002. — Vol. 95, N 9. — P. 1058 — 1059.
- Kullak-Ublick G.A., Barreton G.B. Oswald M. et al. Expression on the hepatocyte canalicular multidrug resistance protein (MRP2) in primary biliary cirrhosis. // Hepatol. Res. 2002. — Vol. 23, N 1. — P. 78 — 82.
- Kupcinskas I., Vitkauskiene A., Petrenkiene V. et al. Detection of H. Pylori PCR analysis in liver biopsy specimens. // J. of Hepatol. 2001. — Vol. 34, Suppl. 1.-P. 185 — 186.
- Kurihara Т., Niimi A., Maeda A. et al. Bezafibrate in the treatment of primary biliary cirrhosis: comparion with ursodeoxycholic acid. // A. J. G. 2000. — Vol. 95, N 10.-P. 2990−2992.
- Lakatos P., Bajnok I. Hegedis D. et al. IL -1 Receptor antagonist gene VNTR polymorphism in Hungarian patients with primary biliary cirrhosis. // J. of Gastroenterol, and Hepatol. 2002. — Suppl. 17. — A. 513.
- Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid' mechanisms of action and clinical use in hepatobiliary disorders'. // J. Hepatol. 2001. — Vol.35,N 1.- P. 134- 146.
- Liermann G.R.F., Evangelista G.C., McMaster P., Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. // Hepatol. 2001. — Vol. 33, N 1. — P. 22 — 27.
- Lindahl T. Repair of intrinsic DNA lesions // Mutat. Res. 1990. — Vol. 238. -P. 305 -311.
- Lindor K.D., Jorgensen R.A., Thermeau T.M. et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. // Mayo Clinic Proccedigs. 1997. — Vol. 72, N 12. — P. 1137 — 1140.
- Lindor K.D., Lacerda M.A., Jorgensen R.A. et al. Relationship between biliary and serym bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. // Amer. J. of Gastroenterol. 1998. — Vol. 93, N 9. -P. 1498- 1504.
- Loeb L.A., Cheng K.C. Errors in DNA synthesis: a cource of spontaneous mutation // Mutat. Res. 1990. — Vol. 238. — P. 297 — 304.
- Long S.A., Quan C., Van de Water J. et al. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: connecting xenobiotics with primary biliary cirrhosis. // J. Immunol. 2001. — Vol. 167, N 5.-P. 2956−2963.
- Luster A.D. Chemokines-chemotactic cytokines that mediate inflammation. // The New England J. of Medicine. 1998. — Vol. 338, N 7. — P. 436 — 445.
- Maestro R.F. An approach to free radicals in medicine and biology // Acta Physiol. Scand. 1980. — Vol. 492. — P. 153 — 168.
- Marklund S. Distribution of Cu, Zn superoxide dismutase and Mn superoxide dismutase in human tissues and extracellular fluids // Physiol. Scand. 1980. -Vol. 92.-P. 19−23.
- Masahito К., Такао М., Tohru Т. et al. Antibodies to E, and E 2 / Protein X components of pyruvate dehydrogenase complex in sera of patients with primary biliary cirrhosis. // J. of Hepatology. 1996. — Vol.25, N 6. — P. 867 -876.
- Mason A., Nair S. Primary biliary cirrhosis: new thoughts on pathophysiology and treatment. // Curr. Gastroenterol. 2002. — Vol. 4, N 1. — P. 45 — 51.
- Mason A.L., Farr G.H., Xu L. et al. Pilot study of lamivudine for patients with primary biliary cirrhosis. // J. of Hepatol., Abstr. of the 36lh Annual Meeting of the Eur. Ass. for the Study of the Liver. -2001.- P/C91/31.
- Mason A.L., Xu L., Guo L. et al. Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. // The Lancet. 1998. -Vol. 351, N30.-P. 1620- 1624.
- Masuda J., Omagari K., Matsuo I. Et al. Changes in titres of antimitochondrial and antibodies during the course of primary biliary cirrhosis. // J. Gastroenterol, and Hepatol.-2001.-Vol. 16, N2.-P. 121 123.
- Masumoto Т., Ninomiya Т., Akbar S.M.F. et al. Determination of the interleukin-2 receptor beta chain by peripheral blood mononuclear cells in patients with primary biliary cirrhosis. // Hepatol. Res.- 1997. Vol. 8, N 3. — P. 207−214.
- Matsumura S., Van de Water J., Kita H. et al. Contribution to antimitochondrial antibody production: cleavage of pyruvate dechydrogenase complex-E2 by apoptosis-related proteases. // Hepatol. 2002. — Vol. 35, N 1. — P. 14 — 22.
- Matsushita M., Miyakawa H., Tanaka A. et al. Single nucleotide polymorphisms of the mannose-binding lectin are associated with susceptibility to primary biliary cirrhosis. // J. Autoimmun. 2001. — Vol. 17, N 3. — P. 251 — 257.
- Mattalia A., Quaranta S., Leung P. S.C. et al. Characterization of antimitochondrial antibodies in healthy adults. // Hepatol. 1998. — Vol. 27, N 3.-P. 656−661.
- Mayo M.J., Combes В., Jenkins R.N. T-cell receptor V p gene utilization in primary biliary cirrhosis. // Hepatol. 1996. — Vol. 24, N 5. — P. 1 148 — 1155.
- Meeberg P.C., Wolfhagen F.H., Berge-Henegouwen G.P. et al. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response. // J. of Hepatol. 1996. — Vol. 25, N 6. -P. 887 — 894.
- Melero S., Spirli C., Zsembery A. et al. Defective regulation of cholangiocyte С1-/НСОЗ (-) and Na+/H+ exchanger activities in primary biliary cirrhosis. // Hepatol. 2002. — Vol. 35, N 6. — P. 1513 — 1521.
- Mitehinson H.C., Palmer J.M., Bassendine M.F. et al. A controlled trial of prednisolone treatment in PBC. Three years results. // J. of Hepatol. 1992. -N 15.-P. 336−344.
- Mitry E., Algayres J.P., Bill H. et al. Autoimmune cholangitis successfully treated by corticotherapy. One case. // Gastroenterol. CI in. et Biol. 1998. -Vol. 22, N 1.-P. 94−97.
- Miyaguchi S., Oda M., Imaeda H. et al. Elevated plasma RANTES in primary biliary cirrhosis patients. // Hepatol. Res. 1997. — Vol. 8, N 3. -P 156 — 163.
- Miyaguchi S., Oda M., Saito H. et al. Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy. // Hepato-Gastroenetrol. -1998.-Vol. 45, N23.-P. 1457- 1461.
- Miyakawa H., Kawaguchi N., Kikuchi K. et al. Definition of antigen specificity for antimitochondrial proteins detected by western blotting using nativemitochondrial proteins in primary biliary cirrhosis. // Hepatol. Res. 2001. -Vol.21,N2.-P. 101−107.
- Miyakawa H., Kawaguchi N., Kikuchi K. et al. False positive reaction in ELISA • for IgM class anti-M2 antibody and prevention. // Hepatol. 2001. — Vol. 20, N3.-P. 279−287.
- Miyakawa H., Kikuchi K., Jong-Hon K. et al. High sensitivity of a novel ELISA for anti-M2 in primary biliary cirrhosis. // J. Gastroenterol. 2001. — Vol. 36, N1.-P. 33 -38.
- Miyakawa H., Tanaka A., Kikuchi K. et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. // Hepatol. 2001. — Vol. 34, N2.-P. 243−248.
- Mohamed-Ali V., Bulmer K., Clarke D. et al. Beta-adrenergic regulation of proinflammatory cytokines in humans. // Int. Obes. Relat. Metab. Disord. -2000.-Vol. 24, Suppl. 2. P. 154- 155.
- Morishita A., Murota M., Fujita J. et al. Helper T lymphocytes specific for cytokeratin 19 in patients with primary biliary cirrhosis. // Hepatol. 2001. -Vol. 21, N2.-P. 108−116.
- Myers R.P., Regimbeau C., Thevenot T. et al. In: The Cochrane Library, Issue
- Oxford: Update Software, 2002.
- Nagano Т., Yamamoto К., Matsumoto S. et al. Cytokine profile in the liver of primary biliary cirrhosis. // J. Clin. Immunol. 1999. — Vol. 19, N 6. — P. 422 -427.
- Nakamura A., Yamazaki K., Suzuki K., Sato S. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. // Amer. J. of Gastroenterol. 1997. — Vol. 92, N 12. — P. 2245−2249.
- Nakano Т., Inoue K., Hirohara J. et al. Long-term prognosis of primary biliary cirrhosis (PBC) in Japan and analysis of the factors of stage progression in asymptomatic PBC (a-PBC). // Hepatol. 2002. — Vol. 22, N 4. — P. 250 — 260.
- Nakanuma Y., Harada K., Kaji K. et al. Clinicopathological study of primary biliary cirrhosis negative for antimitochondrial antibodies. // Liver. 1997. -Vol. 17, N6.-P. 281 -287.
- Neuberger J. Antibodies and primary biliary cirrhosis piecing together the jigsaw. // J. of Hepatol. — 2002. — N 36. — P. 126 — 129.
- Neuman M., Angulo P., Malkiewicz I. Et al. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. // J. Gastroenterol, and Hepatol. 2002. — Vol. 17, N 2. — P. 196−202.
- Neuman M.G., Cameron R.G., Haber J.A. et al. An electron microscopic and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis. // Liver. 2002. — N 22. — P. 235 — 244.
- Nijhawan P.K., Therneau T.M., Dickson E.R. et al. Incidence of cancer in primary biliary cirrhosis: The Mayo experience. // Hepatol. -1999. N 29. — P. 1396- 1398.
- Nishiguchi S., Shiomi S., Ishizu H. et al. Usefulness of scintigraphy with technetium-99m galactosyl human serum albumin in prediction of prognosis of primary biliary cirrhosis. // Hepatol. 2002. — Vol. 22, N 3. — P. 180 — 186.
- O’Donohue J., Fidler H., Garcia-Barcelo M. et al. Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. // J. of Hepatol. 1998. — Vol. 28, N 3. — P. 433 — 438.
- Ochiai H., Sekine H., Ohira H. et al. Analysis of peripheral blood mononuclear cell stimulated with pyruvate dehydrogenase complex, T-cell receptors from- patients with primary biliary cirrhosis. // J. of Gastroenterol. Vol. 33, N 5. — P. 694−701.
- Odin J.A., Huebert R.C., Carciola-Rosen L. et al. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, primary biliary cirrhosis autoantigen, during apoptosis. // J. Clin. Invest. 2001. — Vol. 108, N 2. — P. 223 — 232.
- Okamoto R., Yamamato K., Yabushita K. et al. T cell receptoire in primary biliary cirrhosis: a common T cell clone and receptoire change after treatment. -// J. Clin. Immunol. 2001. — Vol. 21, N 4. — P. 278 — 285.
- Palma J., Reyes H., Ribalta J. et al. Ursodeoxycholic acid in the treatment of • cholestasis of pregnancy: a randomized, double-blind study controlled withplacebo. // J. of Hepatol. 1997. — Vol. 27, N 6. — P. 1022 — 1028.
- Palmer J.M., Kirby J.A., Jones D.E. The immunology of primary biliary cirrhosis: the end of the beginning? // Clin. Exp. Immunol. 2002. — Vol. 129, N2.-P. 191−197.
- Papatheodoridis G.V., Hadziyannis E.S., Deutsch M. et al. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. // Am. J. Gastroenterol. 2002. — Vol. 97, N 8. -P.2063 — 2070.
- Pares A., Caballeria L., Rodes J. et al. Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis. // J. of Hepatol. -2001. Vol. 34, Suppl. 1. — P. 187 — 188.
- Patel D., Egner W., Gleeson D. et al. Detection of serum M2 anti-mitochondrial antibodies by enzyme-linked immunosorbent assay is potentially less specific than by immunofluorescence. // Ann. Clin. Biochem. -2002. Vol. 39, Pt. 3. -P. 304−307.
- Peitsch M.C., Muller Ch., Tschop J. DNA fragmentation during apoptosis is caused by frequent single-strand cuts // Nucl. Acids Res. 1993. — Vol. 21. — P. 4206 — 4209.
- Popivanova N.I., Zaprianov Z., Murdjeva M. et al. Rickettsia induced liver injury: histopathologic findings and cytokine profile. // J. of Hepatol., Abstr. of the 36th Annual Meeting of the Eur. Ass. for the Study of the Liver. 2001. -P/C09/39.
- Poupon R.E., Bonnand A.M., Chretien Y. et al. Ten year survival in ursodeoxy-cholic acid-treated patients with primary biliary cirrhosis. // Hepatology. — 1999. — N 29. — P. 1668 — 1671.
- Poupon R.E., Lindor K.D., Cauch-Dudek K. et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. // Gastroenterol. 1997. — Vol. 113, N 3. — P. 884 — 890.
- Powell F.C., Schroeter A.L., Dickson E.R. Primary biliary cirrhosis and the ¦ CREST syndrome: a report of 22 cases. // Quarterly J. of Medicine. 1987. — N237.-P. 75 -82.
- Powell F.C., Schroeter A.L., Dickson E.R. et al. Case report: acanthosis nigricans in assotiation with primary biliary cirrhosis: resolution after liver transplantation. // J. of Gastroenterol, and Hepatol. 1996. — Vol. 11, N 11. — P. 1021 — 1023.
- Provenzano G., Diquattro O., Graxi A. et al. Immunobloting detection of antibodies to mitochondrial dehydrogenase complexes: a specific test for primary biliary cirrhosis. // Hepatol. Rap. Lit. Rev. 1992. — Vol. N 22, N 9.• P.-299.
- Ramakrishna В., Eapen C.E., Kang G. et al. Familial intrahepatic cholestatic cirrhosis with positive antimitochondrial antibody: familial primary biliary cirrhosis. // J. Clin. Gastroenterol. 2000. — Vol. 30, N 3. — P. 255 — 258.
- Rannard D., Buck D., Jones D.E.J, et al. Evalution of measures used to assess quality of life (QOL) in primary biliary cirrhosis. // J. of Hepatol. 2001. — Vol. 34, Suppl. l.-P. 190.
- Rodrigues C.M., Steer C.J. The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent. // Exp. Opin Inv. Drugs. 2001. — N 10. — P. 1243 -1253.
- Ruediger H.A. A new role TNFalpha in mediating hepatocyte apoptosis in the normothermic ischemic liver. // J. of Hepatol., Abstr. of the 36th Annual Meeting of the Eur. Ass. for the Study of the Liver. 2001. — P/CO1 /63.
- Sakisaka S., Koga H., Sasatomi K. et al. Ursodeoxycholic acid reduces expression of heat shock proteins in primary biliary cirrhosis. // Liver. 2000. -Vol. 20, N 1. — P. 78−87.
- Sanz-Cameno P., Garcia-Monzon C., Majano P.L. et al. Inducible nitric oxide syntese (INOS) liver expression and nitrotyrosine (NTY) accumulation inprimary biliary cirrhosis (PBC) and autoimmune hepatitis (AIN). // J. off h
- Hepatol., Abstr. of the 36 Annual Meeting of the Eur. Ass. for the Study of the Liver.-2001.-P/C03/48.
- Schoninger-Hekele M., Muller C., Ackermann J. et al. Lack of evidence for involvement of fetal microchimerism in pathogenesis of primary biliary cirrhosis.//Dig. Dis. Ski. 2002. — Vol. 47, N9.-P. 1909- 1914.
- Schroeder R.A., Gu J.S., Kuo P.C. Interleukin 1 beta-stimulated production of. nitric oxyde in rat hepatocytes is mediated through endogenous synthesis ofinterferon gamma. // Hepatol. 1998. — Vol. 27, N 3. — P. 711 — 719.
- Schuchman M., Galle H.R. Apoptosis in liver disease. // Eur. J. of Gastroenter. and Hepatol. 2001. — N 13. — P. -785 — 790.
- Seibold F., Weber P., Schoning A. et al. Neutrophil antibodies (pANA) in chronic liver disease and inflammatory bowel disease: do they react with different antigens? // European J. of Gastroenterol, and Hepatol. 1996. — Vol. 8, N11.-P. 1095- 1100.
- Shibata M., Morizane Т., Tanaka A. et al. A case of autoimmune hepatitis with • a high titer of antimitochondrial antibody and normal gamma-globulinemia. // J.
- Gastroenterol, and Hepatol. 2001. — Vol. 16, N 7. — P. 830 — 835.
- Shiina M., Kobayashi K., Mano Y. et al. Up-regulation of CDlla (LFA-1) expression on peripheral CD4+ T cells in primary biliary cirrhosis. // Dig. Dis. Sci.-2002.-Vol. 47, N6.-P. 1209- 1215.
- Sorda J., Findor J. Methotrexate therapy in primary biliary cirrhosis. // Acta Gastroenterol. Latinoamer. 2000. — Vol. 30, N 4. — P. 266 — 267.
- Steinke D.T., Weston T.L., Morris A.D. et al. Incidence, prevalence and resource use of primary biliary cirrhosis in Tayside, Scotland. // J. of Hepatol. -2001.-Vol. 34, Suppl. l.-P. 181.
- Stone J., Wade J.A., Cauch-Dudek K. et al. Human leucocyte antigen Class II associations in serum antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. // J. Hepatol. 2002. — Vol.36, N 1. — P. 8 -13.
- Strassburg C.P., Manns M.P. Autoimmune tests in primary biliary cirrhosis. // Baill. Best Pract. Res. Clin. Gastroenterol. Vol. 14, N 4. — P. 585 — 599.
- Strater J., Moller P. Pathogenesis of primary biliary cirrhosis: CD95-induced apoptosis at last? // Eur. J. of Gastroenterol, and Hepatol. 1998. — Vol. 10, N 7.-P. 539−541.
- Szalay F. Treatment of primary biliary cirrhosis. // J. Physiol. Paris. 2001. — N 95.-P. 407−412.
- Tanaka A., Borchers A.T., Ishibashi H. et al. Genetic and familial considerations of primary biliary cirrhosis. // Am. J. Gastroenterol. 2001. -Vol. 96, N l.-P. 8−15.
- Tanaka A., Miyakawa H., Luketic V.A. et al. The diagnostic value of antimitochondrial antibodies, especially in primary biliary cirrhosis. // Cell. Mol. Biol. 2002. — Vol. 48, N 3. — P. 295 — 299.
- Tanaka A., Nalbadian G., Leung P. S. et al. Mucosal immunity and primary biliary cirrhosis: presence of antimitochondrial antibodies in urine. // Hepatol. -2000. Vol. 32, N 5. — P. 910 — 915.
- The WHOQOL Group. What Quality of Life? // World Health Forum. 1996. -Vol. 17, N4.-P. 354−356.
- Tinmouth J., Lee M., Wanless l.R. et al. Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. // Liver. 2002. -Vol. 22, N3. — P.-228−234.
- Tinmouth J., Tomlinson G., Heathote E.J. et al. Benefit of transplantation in primary biliary cirrhosis. // Transpl. 2002. — Vol. 73, N 2. — P. 224 — 227.
- Tojo J., Ohira H., Suzuki T. et al. Clinicolaboratory characteristics of patients with primary biliary cirrhosis associated with CREST symptoms. // Hepatol. Res. 2002. — Vol. 22, N3.-P. 187- 195.
- Tsuneyama K., Harada K., Kono N. et al. Scavenger cells with gram-positive bacterial lipoteichoic acid infiltrate around the damaged interlobular mile ducts of primary biliary cirrhosis. // J. Hepatol. 2001. — Vol. 35, N 2. — P. 156 — 163.
- Tsuneyama K., Yasoshima M., Harada K. et al. Increased CD Id expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. // Hepatol. 1998. — Vol. 28, N 3. — P. 620 — 623.
- Ueno Y., Ishii M., Mano Y. et al. Primary biliary cirrhosis with antibody against carbonic anhydrase II associates with distinct immunological backgrounds. // Hepatol. Res. 2001. — N 20. — P. 18 — 27.
- Verma A., Jazrawi R.P., Ahmed H.A. et al. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis. // Eur. J. Gastroenterol, and Hepatol. 1999. -Vol. 11, N10.-P. 1069- 1076.
- Vilagut L., Pares A., Vinas O. et al. Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis. // Eur. J. of Clin. Invest. 1997. N 27. — P. 667 — 672.
- Vleggaar F.P., Van Buuren H.R., Zondervan P.E. et al. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. // Gut. 2001. — N 49.-P. 276−281.
- Ware J.E., Sherbourne C. // Med. Care. 1992. — Vol. 20. — P. 473 — 483.
- Wassmuth R., Depner F., Danielsson A. et al. HLA class II markers and clinical heterogeneity in Swedish patients with primary biliary cirrhisis. // Tissue Antigens. 2002. — Vol. 59, N 5. — P. 381 — 387.
- Watanabe S., Deguchi A., Uchida N. et al. Histopathologic comparison of anti-mitochondrial antibody-positive primary biliary cirrhosis and autoimmune cholangiopathy. // Hepatol. 2001. — Vol. 19, N 1. — P. 41 — 51.
- Watson J.P., Jones D.E., James O.F. et al. Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. // J. Gastroenterol, and Hepatol. 1999.-Vol. 14, N 10.-P. 1034- 1040.
- Wyllie A., Kerr J., Currie A. The significance of apoptosis // Intern. Rev. Cytol. 1980.-Vol. 68.-P. 251.
- Yamaguchi H., Miura H., Ohsumi K. et al. Detection and characterization of antibodies to bacterial heat-shock protein 60 in sera of patients with primary biliary cirrhosis. // Microbiol. Immunol. 1994. — Vol. 38, N 6. — P. 483 — 487.
- Yeaman S.J., Jones D.E., Palmer J.M. et al. Experimental autoimmune. cholangitis: a mouse model of immune-mediated cholangiopathy. // Liver.2000. Vol. 20, N 5. — P. 351 — 356.
- Yeaman S.J., Kirby J.A., Jones D.E. Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis. // Immunol. Rev. 2000. — N 174. — P. 238 — 249.
- Younossi Z.M., Boparai N., Price L.L. et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. // A.M.J.Gastroenterol. 2001. — N 96. — P. 2199 — 2205.
- Younossi Z.M., Kiwi M.L., Boparai N. et al. Cholestatic liver diseases and • health-related quality of life. // Am. J. Gastroenterol. 2000. — Vol. 95, N 2.1. P. 497 502.bfi Q
- Zukowski Т.Н., Jorgensen R.A., Dickson E.R. et al. Autoimmune conditions • associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy. // Amer. J. of Gastroenetrol. 1998. — Vol. 93, N 6. — P. 958 — 961.